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Abstract
Background: Myocardial infarction can be difficult to diagnose after lung surgery. As recent
diagnostic criteria emphasize serum cardiac markers (in particular serum troponin) we set out to
evaluate its clinical utility and to establish the long term prognostic impact of detected abnormal
postoperative troponin levels after lung resection.
Methods: We studied a historic cohort of patients with primary lung cancer who underwent
intended surgical resection. Patients were grouped according to known postoperative troponin
status and survival calculated by Kaplan Meier method and compared using log rank. Parametric
survival analysis was used to ascertain independent predictors of mortality.
Results: From 2001 to 2004, a total of 207 patients underwent lung resection for primary lung
cancer of which 14 (7%) were identified with elevated serum troponin levels within 30 days of
surgery, with 9 (64%) having classical features of myocardial infarction.
The median time to follow up (interquartile range) was 22 (1 to 52) months, and the one and five
year survival probabilities (95% CI) for patients without and with postoperative troponin elevation
were 92% (85 to 96) versus 60% (31 to 80) and 61% (51 to 71) versus 18% (3 to 43) respectively
(p < 0.001).
T stage and postoperative troponin elevation remained independent predictors of mortality in the
final multivariable model. The acceleration factor for death of elevated serum troponin after
adjusting for tumour stage was 9.19 (95% CI 3.75 to 22.54).
Conclusion: Patients with detected serum troponin elevation are at high risk of early mortality
with or without symptoms of myocardial infarction after lung resection.
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Background
Postoperative myocardial infarction is not a well studied
topic after lung surgery. From the few reports in the liter-
ature, the frequency to range between 0.7% to 2% [1,2],
but it is difficult to determine an exact standarized inci-
dence, in part due to differences in postoperative presen-
tation, differences in EKG interpretation and a variation in
the choice of serum cardiac markers.
Recently, the diagnostic criteria for myocardial infarction
has evolved from a history of chest pain, EKG changes and
a rise in serum cardiac markers, to an emphasis on serum
cardiac markers (in particular serum troponin) as the pri-
mary diagnostic modality [3]. The normal postoperative
profile of cardiac markers has only recently been estab-
lished. In contrast to CK-MB, both cardiac troponin T and
I are unaffected by routine thoracic (non-cardiac) surgery
[4], supporting troponin as the cardiac marker of choice in
this setting.
To evaluate the clinical utility of troponin assay after lung
surgery, we set out to assess the frequency of classical sup-
porting features of myocardial infarction and to establish
the long term prognostic impact of detected abnormal
postoperative troponin levels in patients who underwent
lung resection for primary lung cancer.
Methods
We studied a historic cohort of patients from 2001 to
2004 (the start date reflects the availability of troponin
assay at our institution) with known or suspected primary
lung cancer who underwent intended surgical resection.
As cervical mediastinoscopy and biopsies were performed
prior to thoracotomy for all patients with clinically sus-
pected N2 disease, additional lymph node sampling was
only undertaken in selected patients with unexpected or
suspicious findings during thoracotomy. Staging was per-
formed according to Mountain 1997 [5]. We excluded
patients that did not prove to have primary lung cancer on
histopathologic examination.
Data acquisition
Patients were identified from our hospital National
Health Service (NHS) database of Office of Population,
Censuses and Surveys – Classification of Surgical Opera-
tions and Procedures codes (OCPS), and data obtained
from case notes and histopathology reports. Survival was
documented as the date of last follow up in a hospital out-
patient clinic, and mortality documented as the date of
death from patient records or the NHS strategic tracing
service (NHS, UK).
Troponin assay
Troponin I was analysed using the Access® AccuTnI™ tro-
ponin I assay (Beckman Coulter Inc., CA, USA) with 0.04
μg/l as the upper reference limit of normal. The pathology
database was screened for each patient individually to
determine if a troponin sample was requested. Troponin
levels of 0.04 μg/l or more within 30 days of surgery were
classified as elevated in this study. Patients were grouped
according to the presence of known  post operative tro-
ponin elevation, and patients with normal or no known
postoperative troponin levels were classified as "no tro-
ponin elevation".
Statistical analysis
Categorical data are presented as frequency (%) and con-
tinuous data as mean with standard deviation (SD) or
median with interquartile range (IQR). Comparisons of
baseline categorical data between the two groups were
made using Fisher's exact test and continuous data com-
pared using two tailed t-test.
Parametric and non-parametric survival analyses were
applied. Actuarial survival was estimated using the Kap-
lan-Meier method and compared using the Log-rank test.
to Parametric survival analysis (log-logistic accelerated
failure time model) was used to model the hazard func-
tion, ascertain the individual contribution of factors asso-
ciated with survival and to compare the risk adjusted
survival between the two groups. The survival analysis was
repeated with non-parsimonious propensity score multi-
variable adjustment, and one-to-one (nearest neighbor)
matching on age, sex, tumour stage, nodal status and
operation extent. Statistical analyses were performed
using R version 2.0.0 [6].
Results
From 1st January 2001 to 1st January 2004, a total of 231
patients underwent lung resection for the presumed diag-
nosis of primary lung cancer. We excluded 26 patients
who did not prove to have primary lung cancer. Of the
205 patients remaining, 41 had a troponin sample
requested, 19 were elevated, of which 14 (7%) were ele-
vated within 30 days of surgery. The remaining 5 patients
in which the troponin levels were detected as elevated
more than 30 days from surgery were analysed in the no
troponin elevation group. The mean age (SD) of the
cohort was 66 (11) years, and 133 (65%) were men. The
baseline characteristics of the two groups are summarised
in table 1.
Of the 14 patients with elevated postoperative troponin
levels, the mean peak level was 0.936 μg/l, and the major-
ity (10/14) were detected within the first 5 postoperative
days (Figure 1). In total, 5 had a preoperative history of
stable ischaemic heart disease (4 had angina, 1 had a his-
tory of previous myocardial infarction). The main docu-
mented indication for postoperative troponin estimation
was atrial fibrillation in 6 patients (department policy forJournal of Cardiothoracic Surgery 2006, 1:37 http://www.cardiothoracicsurgery.org/content/1/1/37
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screening patients with new onset postoperative atrial
fibrillation), investigation of low blood pressure in 4
patients, postoperative chest pain in 2 patients and inves-
tigation of dyspnea in 2 patients. The revised definition
for myocardial infarction (enzyme elevation accompa-
nied by either supportive ECG changes or chest pain) was
achieved in 9 patients (64%), with 5 fulfilling the criteria
for ST elevation myocardial infarction and 3 fulfilling the
criteria for non-ST-elevation myocardial infarction (one
patient with chest pain and troponin elevation did not
have any ECG changes of ischaemia).
The median time to follow up (interquartile range) was 22
(1 to 52) months, with the one and five year survival
probabilities (95% CI) for patients without and with post-
operative troponin elevation as 92% (85 to 96) versus
60% (31 to 80) and 61% (51 to 71) versus 18% (3 to.43)
respectively (p < 0.001, Figure 2).
The univariable prognostic predictors are summarised in
table 2, and postoperative troponin elevation and T stage
remained as independent predictors of mortality in the
final multivariable model (table 3). The acceleration fac-
tor for mortality in patients with known postoperative tro-
ponin elevation was exp-(-2.218), corresponding to 9.19
(95% CI 3.75 to 22.54).
For patients with known troponin elevation, the instanta-
neous risk of death (hazard function, Figure 3) was high-
est in the first six months before gradually declining. This
was in contrast to patients without (known) elevated
postoperative levels where a small initial rise was fol-
lowed by a relatively constant hazard for death.
When propensity score multivariable adjusted analysis as
performed the results remained highly significant for early
mortality in patients with known elevated troponin eleva-
tion (-2.30, p < 0.001) with a non-significant p-value for
the coefficient for the propensity score (p = 0.11). The
results remained robust even with one-to-one matching of
the 14 patients with known elevated troponin levels to
controls (-2.06, p < 0.001).
Discussion
Normally, troponin is not detectable in the serum after
lung surgery [4,7]. The results from our study reveal the
Table 1: Baseline characteristics by group
No troponin elevation Troponin elevation P value
Number 191 14
Mean age, yrs (SD) 66 (11) 72 (5) 0.001
Men, n(%) 123 (64) 10 (71) 0.774
Operation extent
Pneumonectomy, n(%) 45 (24) 5 (36)
Lobectomy, n(%) 135 (70) 8 (57) 0.424
Other, n(%) 12 (6) 1 (7)
Cell type
Squamous, n(%) 83 (43) 7 (50)
Adenocarcinoma, n(%) 68 (36) 5 (36)
Large cell, n(%) 6 (3) 0 (0) 0.902
Mixed, n(%) 12 (6) 1 (7)
Other, n(%) 24 (12) 1 (7)
T category
T1, n(%) 42 (22) 2 (14)
T2, n(%) 112 (58) 10 (72)
T3, n(%) 14 (7) 1 (7) 0.955
T4, n(%) 6 (3) 0 (0)
Tx, n(%) 19 (10) 1 (7)
N category
N0, n(%) 111 (58) 7 (50)
N1, n(%) 46 (24) 5 (36)
N2, n(%) 17 (8) 1 (7) 0.811
Nx, n(%) 19 (10) 1 (7)Journal of Cardiothoracic Surgery 2006, 1:37 http://www.cardiothoracicsurgery.org/content/1/1/37
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prognostic impact of detected elevated postoperative
serum troponin levels, which is associated high risk of
early death.
The relationship to myocardial infarction is more difficult
to delineate, as 36% (5/14) of patients with elevated
serum troponin levels did not have chest pain or EKG evi-
dence of ischemia. After thoracic surgery, we routinely use
thoracic epidural analgesia supplemented with non-opi-
ate oral analgesics. We believe that this practice is com-
mon and potentially attenuates symptoms of ischaemic
chest pain. In addition, it might be more difficult for
patients to distinguish between new onset chest pains
against the background of thoracotomy wound pain.
Classical ST-elevation on EKG was present in only 5
(36%) patients. Therefore, it can be difficult to establish a
diagnosis of postoperative myocardial infarction in the
setting of thoracic surgery.
Serum troponin levels may be useful in this regard, apart
from greater cardio-specificity (compared to CK-MB),
minute elevations were able to convey long term prognos-
Cumulative frequency plot of time to detection of troponin elevation Figure 1
Cumulative frequency plot of time to detection of troponin elevation.
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tic information. The upper reference limit (0.04 μg/l) in
our study was five times lower than the reference limit of
0.20 μg/l required by the assay used in Vikenes et al. [4].
On one end of the spectrum of severity of myocardial inf-
arction, myocardial necrosis detected on isolated serum
troponin elevation may be a specific method to identify
patients at a high risk of early death (within six months of
surgery). Established postoperative myocardial infarction
lies on the other extreme of the spectrum, and raises the
30-day mortality by an odds ratio of 32 [2]. The longer
term consequences and impact on survival have not been
quantified.
Clinical implications
We highlight a potential use for serum troponin as a
screening investigation to identify patients with a poor
prognosis, regardless of further symptoms of myocardial
infarction. This is consistent with observation that iso-
lated troponin elevation is an independent predictor of
mortality across the spectrum of the chest pain syndromes
[8]. In total 6 (43%) patients were identified as part of a
screening policy for new onset atrial fibrillation, suggest-
ing that this may be a common presentation of postoper-
ative myocardial infarction or (more accurately)
myocardial necrosis without clinical evidence of infarc-
tion.
Survival by postoperative troponin status Figure 2
Survival by postoperative troponin status. Kaplan Meier estimates are represented by circles in the group with no known 
troponin elevation, and squares in the group with known troponin elevation. The lines are the fitted parametric survival esti-
mates.
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An unfortunate corollary of the retrospective nature of our
study is the inability to confidently identify the patient
risk factors that are associated with troponin elevation.
Although patients with postoperative troponin elevation
were significantly older, age alone is not a powerful dis-
criminating feature. At a rate of 7% (95% CI 4 to 11) and
estimated 9 fold acceleration in the risk of death, the clin-
ical utility of serum troponin estimation after lung resec-
tion appears to be an important topic for further study.
Importantly, only 5 of the 14 patients had a preoperative
history of ischaemic heart disease, of which all had symp-
toms of stable angina and good performance status, not
meeting the accepted criteria for further cardiovascular
screening [9] The results of our study highlight the limita-
tions of such recommendations, and suggest the need for
further work in this area.
To date, there are no guidelines that address the manage-
ment of myocardial infarction specifically after thoracic
surgery. General guidelines for non-cardiac surgery stress
the need for medical management (aspirin, beta-blockers,
ACE inhibitors) and risk factor modification for second-
ary prevention [9]. Despite these efforts, survival in our
cohort remained poor. Not all options are available, as
thrombolysis is contraindicated after major thoracic sur-
gery. Further work is required to determine if a more
aggressive approach (primary angioplasty and stenting)
could improve outcome, however, primary percutaneous
coronary intervention also requires the use of anti-platelet
agents, heparin and will be limited only to institutions
where this facility is available.
Potential limitations
The main limiting factors are the retrospective study
design on a relatively small group rendering our study sus-
ceptible to bias. Unfortunately, sample size was limited by
the relatively recent introduction of troponin assay at our
institution. We have assumed that atrial fibrillation was
associated with myocardial necrosis as we have found no
evidence to suggest that atrial fibrillation alone elevates
serum troponin independently of myocardial necrosis.
However, our findings are not altered in respect of this
relationship. Although we were not able to adjust for pre-
operative lung function in our analyses, the mean preop-
erative FEV1 of 2.2 l in patients in the troponin elevation
arm was not different from our usual preoperative patient
population.
Future directions
It is clear that serum troponin is rapidly becoming the car-
diac marker of choice, and prospective studies on unse-
lected patients will be able to more accurately establish its
utility as a prognostic marker. Further work would be able
to determine if elevated troponin levels result from proce-
dures that involve the pericardium (intra pericardial
pneumonectomies), and ascertain if it carries similar
prognostic implication.
Conclusion
After lung surgery, approximately a third of patients with
troponin elevation do not have classical symptoms of
myocardial infarction. Atrial fibrillation was a common
presenting feature leading to the identification of elevated
serum troponin. Patients with detected serum troponin
Table 2: Univariable predictors of mortality
Variable Coefficient (α) SE P value
Troponin elevation -0.016 0.015 < 0.001
Age, per yr -0.016 0.015 0.300
Male sex -0.200 0.298 0.503
T category
T1 1.000
T2 -0.475 0.393 0.227
T3 -1.080 0.566 0.056
T4 -1.141 0.684 0.095
Tx 1.119 0.721 0.120
N category
N0 1.000
N1 -0.128 0.304 0.675
N2 -0.313 0.486 0.519
Nx 1.555 0.671 0.020
Operation
Pneumonectomy 1.000
Lobectomy 0.493 0.306 0.107
Other resection 0.948 0.563 0.093
Cell type
Squamous 1.000
Adenocarcinoma -0.057 0.303 0.850
Large cell -1.038 0.797 0.193
Mixed -0.228 0.589 0.699
Other 1.109 0.584 0.058
*Exponentiation of the negative of the coefficient, exp(-α) will give the 
acceleration factor
Table 3: Multivariable predictors of mortality
Variable Coefficient (α) SE P value
Troponin elevation -2.218 0.458 < 0.001
T0 1.000
T2 -0.425 0.379 0.263
T3 -1.196 0.527 0.023
T4 -1.291 0.638 0.043
Tx 0.856 0.662 0.196
*Exponentiation of the negative of the coefficient, exp(-α) will give the 
acceleration factorJournal of Cardiothoracic Surgery 2006, 1:37 http://www.cardiothoracicsurgery.org/content/1/1/37
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elevation are at high risk of early mortality after lung
resection for primary lung cancer.
Acknowledgements
We gratefully acknowledge the contribution of Anoop Alka, and Sharon 
Atkinson (Norfolk and Norwich University Hospital) for the assistance in 
patient data retrieval and acquisition individual serum troponin levels.
References
1. Yano T, Yokoyama H, Fukuyama Y, Takai E, Mizutani K, Ichinose Y:
The current status of postoperative complications and risk
factors after a pulmonary resection for primary lung cancer.
A multivariate analysis.  Eur J Cardiothorac Surg 1997, 11:445-449.
2. Ploeg AJ, Kappetein AP, van Tongeren RB, Pahlplatz PV, Kastelein
GW, Breslau PJ: Factors associated with perioperative compli-
cations and long-term results after pulmonary resection for
primary carcinoma of the lung.  Eur J Cardiothorac Surg 2003,
23:26-29.
3. Alpert JS, Thygesen K, Antman E, Bassand JP: Myocardial infarction
redefined--a consensus document of The Joint European
Society of Cardiology/American College of Cardiology Com-
mittee for the redefinition of myocardial infarction.  J Am Coll
Cardiol 2000, 36:959-969.
4. Vikenes K, Andersen KS, Farstad M, Nordrehaug JE: Temporal pat-
tern of cardiac troponin I after thoracotomy and lung sur-
gery.  Int J Cardiol 2004, 96:403-407.
5. Mountain CF: Revisions in the International System for Stag-
ing Lung Cancer.  Chest 1997, 111:1710-1717.
6. R Development Core Team (2006). R: A language and envi-
ronment for statistical computing. R Foundation for   Statis-
tical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL
http://www.R-project.org.  .
7. Katus HA, Schoeppenthau M, Tanzeem A, Bauer HG, Saggau W, Die-
derich KW, Hagl S, Kuebler W: Non-invasive assessment of peri-
Hazard function by postoperative troponin status. Figure 3
Hazard function by postoperative troponin status.
Time after surgery (months)
H
a
z
a
r
d
 
f
u
n
c
t
i
o
n
0 6 12 18 24 30 36 42 48 54 60
0
0
.
0
2
0
.
0
4
0
.
0
6
0
.
0
8
0
.
1
Troponin elevation
No troponin elevationPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Cardiothoracic Surgery 2006, 1:37 http://www.cardiothoracicsurgery.org/content/1/1/37
Page 8 of 8
(page number not for citation purposes)
operative myocardial cell damage by circulating cardiac
troponin T.  Br Heart J 1991, 65:259-264.
8. Rao SV, Ohman EM, Granger CB, Armstrong PW, Gibler WB, Chris-
tenson RH, Hasselblad V, Stebbins A, McNulty S, Newby LK: Prog-
nostic value of isolated troponin elevation across the
spectrum of chest pain syndromes.  Am J Cardiol 2003,
91:936-940.
9. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann
KE, Fleisher LA, Froehlich JB, Gusberg RJ, Leppo JA, Ryan T, Schlant
RC, Winters WL Jr, Gibbons RJ, Antman EM, Alpert JS, Faxon DP,
Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith
SC Jr: ACC/AHA Guideline Update for Perioperative Cardi-
ovascular Evaluation for Noncardiac Surgery--Executive
Summary A Report of the American College of Cardiology/
American Heart Association Task Force on Practice Guide-
lines (Committee to Update the 1996 Guidelines on Periop-
erative Cardiovascular Evaluation for Noncardiac Surgery).
Circulation 2002, 105:1257-1267.